Inhibikase Therapeutics Inc (IKT) Stock Analysis

Inhibikase Therapeutics Inc (IKT) is a publicly traded company in the HEALTHCARE sector. It trades at $1.70, carries a market capitalization of $231.06M. This page summarizes the public market data, fundamentals, and frequently asked questions for IKT, with GNG Research's proprietary safety, quality, and valuation analysis available to members.

Sector: HEALTHCARE - BIOTECHNOLOGY

Exchange: NASDAQ

Key Metrics

Market Sentiment

Inhibikase Therapeutics Inc currently has a Bullish sentiment score of 0.17.

About Inhibikase Therapeutics Inc

Inhibikase Therapeutics, Inc. is a clinical-stage pharmaceutical company headquartered in Atlanta, Georgia, dedicated to advancing innovative therapies for Parkinson's disease (PD) and related neurodegenerative disorders. The company employs a novel dual-targeting approach that addresses both central and peripheral mechanisms of neurodegeneration, aiming to tackle significant unmet medical needs within the PD patient population. With a robust pipeline of therapeutics currently in clinical dev...

GNG Research Analysis

GNG Research scores Inhibikase Therapeutics Inc (IKT) on three proprietary dimensions — a Safety score, a Quality score, and a Valuation score — alongside fair value estimates and buy-price targets for 5,000+ companies. These ratings are reserved for members. Read how the scores are calculated on our methodology page, or see GNG Research plans to unlock the full rating for IKT.

Frequently Asked Questions

Does IKT pay dividends?

Inhibikase Therapeutics Inc (IKT) does not currently pay a regular dividend.

What is IKT's market cap?

Inhibikase Therapeutics Inc (IKT) has a market capitalization of $231.06M with a current stock price of $1.70.